Veloxis Pharmaceuticals AS (VELO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012275
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company, which develops therapies for kidney transplantation based on its proprietary MeltDose platform. MeltDose is a drug delivery technology, used to enhance oral bioavailability and control release of a drug. The company’s product portfolio consists of Envarsus XR, anti-rejection drug for patients who had kidney transplantation; and Fenoglide for the treatment of dyslipidemia. The company out licensed the commercial rights of Fenoglide for the US, Canada and Mexico; and Envarsus to Chiesi in Europe, Turkey and CIS countries. It has a wholly owned subsidiary, Veloxis Pharmaceuticals Inc., in New Jersey, the US. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS (VELO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 10
Veloxis Pharma Enters Into Co-Development Agreement With Athena Drug Delivery Solutions 12
Licensing Agreements 13
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 13
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 14
Taiba Pharma Enters into Licensing Agreement with Veloxis Pharma 15
Equity Offering 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 17
Veloxis Pharma Raises USD0.6 Million in Private Placement of Shares 18
Veloxis Pharmaceuticals A/S – Key Competitors 19
Veloxis Pharmaceuticals A/S – Key Employees 20
Veloxis Pharmaceuticals A/S – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Nov 14, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017 22
Aug 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017 23
May 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017 24
Feb 28, 2017: Veloxis Pharmaceuticals Releases Annual Report for 2016 25
Nov 16, 2016: Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2016 26
Aug 24, 2016: Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2016 and Provides Corporate Update 27
May 18, 2016: Veloxis Pharmaceuticals announces financial results for the first three months of 2016 28
Mar 09, 2016: Veloxis Pharmaceuticals publishes Annual Report 2015 31
Corporate Communications 32
Sep 20, 2017: Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals 32
Sep 13, 2017: Veloxis Pharmaceuticals Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer 33
Jul 26, 2016: Veloxis Pharmaceuticals Passing of Extraordinary General Meeting 34
Apr 06, 2016: Veloxis announces change in management 35
Feb 29, 2016: Veloxis appoints Alastair McEwan as new Chief Operating Officer 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Veloxis Pharmaceuticals A/S, Deals By Therapy Area, 2011 to YTD 2017 8
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 10
Veloxis Pharma Enters Into Co-Development Agreement With Athena Drug Delivery Solutions 12
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 13
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 14
Taiba Pharma Enters into Licensing Agreement with Veloxis Pharma 15
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 17
Veloxis Pharma Raises USD0.6 Million in Private Placement of Shares 18
Veloxis Pharmaceuticals A/S, Key Competitors 19
Veloxis Pharmaceuticals A/S, Key Employees 20
Veloxis Pharmaceuticals A/S, Subsidiaries 21

★海外企業調査レポート[Veloxis Pharmaceuticals AS (VELO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ichor Holdings Ltd (ICHR):企業の財務・戦略的SWOT分析
    Ichor Holdings Ltd (ICHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Vail Resorts Inc:戦略・SWOT・企業財務分析
    Vail Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Vail Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Berkshire Hathaway Energy Co:石油・ガス:M&Aディール及び事業提携情報
    Summary Berkshire Hathaway Energy Company (BHE) a subsidiary of Berkshire Hathaway Inc., generates, transmits, stores, distributes, and supplies electricity; and procures, transports, distributes and sells natural gas through its subsidiaries. It generates power through diversified energy sources su …
  • Dragon Oil Plc:企業の戦略的SWOT分析
    Dragon Oil Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Valeritas Inc:医療機器:M&Aディール及び事業提携情報
    Summary Valeritas Inc (Valeritas) is a medical technology company that develops and commercializes treatment solutions for diabetes. The company’s product includes V-Go insulin delivery device a wearable basal-bolus insulin delivery solution for patients with Type 2 diabetes. It also provides V-Go l …
  • Dining Street Ltd:企業の戦略・SWOT・財務分析
    Dining Street Ltd - Strategy, SWOT and Corporate Finance Report Summary Dining Street Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Encompass Home Health and Hospice-製薬・医療分野:企業M&A・提携分析
    Summary Encompass Home Health and Hospice (Encompass), formerly CareSouth Health System Inc, is a healthcare service provider that offers nursing care services. The center provides services including home healthcare, private duty home care, hospice, and health and wellness services. It offers manage …
  • Galera Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Galera Therapeutics Inc (Galera Therapeutics) is a clinical stage biotechnology company that discovers and develops novel cancer treatments. The company also concentrates on the prevention of radiation-induced toxicity including mucositis and the treatment of cancer. Its GC4419 is a selectiv …
  • Power Assets Holdings Limited:企業の戦略・SWOT・財務情報
    Power Assets Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Power Assets Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Premaitha Health Plc (NIPT):医療機器:M&Aディール及び事業提携情報
    Summary Premaitha Health Plc (Premaitha Health), formerly Vialogy Plc, is a molecular diagnostics company, which focuses on the development of genetic screening tests including novel tests for non-invasive prenatal screening (NIPT). Its flagship product, the IONA test is an advanced NIPT test that a …
  • Boralex Inc (BLX):電力:M&Aディール及び事業提携情報
    Summary Boralex Inc (Boralex) is a renewable energy company. It develops, builds, and operates renewable energy power facilities. The company’s asset portfolio includes wind, hydro, thermal, and solar projects. Boralex also has interests in various projects under development stages. Under long-term …
  • Bharat Sanchar Nigam Ltd:企業の戦略的SWOT分析
    Bharat Sanchar Nigam Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • New Age Metals Inc:企業の戦略・SWOT・財務情報
    New Age Metals Inc - Strategy, SWOT and Corporate Finance Report Summary New Age Metals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Noel Gifts International Ltd. (543):企業の財務・戦略的SWOT分析
    Noel Gifts International Ltd. (543) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Wartsila Corporation (WRT1V)-エネルギー分野:企業M&A・提携分析
    Summary Wartsila Corporation (Wartsila) offers a complete lifecycle power solutions and advanced technologies for the marine and energy markets. It provides low- and medium-speed engines, seals and bearings, automation systems, pumps and valves, ship design and ballast water treatment systems to shi …
  • CMS Energy Corp (CMS):企業の財務・戦略的SWOT分析
    CMS Energy Corp (CMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Empresa Electrica Corani SA (COR1U):電力:M&Aディール及び事業提携情報
    Summary Empresa Electrica Corani SA (Empresa Electrica), a subsidiary of Empresa Nacional de Electricidad Bolivia, is a renewable energy company that develops and operates hydroelectric power plants and wind farms. The company offers operation and maintenance, project development, and technical serv …
  • Robert Half International Inc.:企業の戦略・SWOT・財務情報
    Robert Half International Inc. - Strategy, SWOT and Corporate Finance Report Summary Robert Half International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • MSCI Inc. (MSCI):企業の財務・戦略的SWOT分析
    MSCI Inc. (MSCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Altimmune Inc-製薬・医療分野:企業M&A・提携分析
    Summary Altimmune Inc (Altimmune), formerly Vaxin Inc is a biotechnology company that develops vaccines and other biological products. The company's products include novel vaccine delivery platforms, immunotherapeutic products, intranasally administered recombinant influenza vaccine, traditional inf …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆